Latest News

Autolus Therapeutics aiming for NASDAQ IPO

This April, Autolus Therapeutics and Miltenyi Biotec inked a long-term agreement on the supply and support of Miltenyi Biotec’s CliniMACS Prodigy instruments, reagents and disposables for the manufacture of Autolus’ programmed T cell therapies. © Miltenyi Biotec


by tg

British T cell player, Autolus Therapeutics Ltd. wants to go NASDAQ selling 7.8 million American Depositary Shares (ADSs) at  at least US-$15, totaling in US$117m. Through a greenshoe option, Autolus want to offer additional 1,171,875 ADS at the IPO price. 

Goldman Sachs & Co. LLC and Jefferies LLC are acting as joint book-running managers for the offering. Wells Fargo Securities, LLC and William Blair & Company, L.L.C. are acting as lead managers.

The company is well-financed. Last September, Autolus added a US$80m Series C equity funding to US$96m raised in previous financing rounds led by Syncona Ltd., Woodford Investment Management, and Arix Bioscience plc.

Autolus‘ T cell therapies target the the blood cancer ALL either through CD19 (in Phase I) a similar approach to approved CAR-T cell therapies from Novartis and Gilead Sciences, or through targeting CD19 and CD22 (Phase I/II). The company's CD19 candidate however is claimed "next-generation" due to its fast CD19 dissociation kinetics, which allows to target many CD19+ cells very rapidly. Furthermore, the company’s CAR-T cells target CD269 and TACI to treat multiple myeloma (Phase I/II). An additional candidate undergoing Phase I safety testing targets GD2, a disialoganglioside expressed on tumours of neuroectodermal origin, to treat the rare childhood brain cancer neuroblastoma.

Numab AG bags CHF70m in licencing deal

Under the agreement, Intarcia Therapeutics will pay up to CHF70m to gain exclusive, global rights for commercialisation of the preclinical...

uniqure delivers POC for hemophilia B gene therapy

AMT-061, an AAV5 vector, expresses a gene cassette with the Padua variant of Factor IX, which lacks in hemophilia B patients. According to uniqure,...

Valneva inks $59m JE vaccine supply contract

Under the agreement, Valneva will supply its FDA-approved preventive vaccine for Japanese encephalitis (JE) from 2019 to 2020. There is a minimum...

AMR Conference in Berlin: Call for better incentives

"We need the political willingness to put money on the table", said Peter Beyer, Senior Advisor at the World Health Organisation at the...

Hookipa Pharma files for US-$86m IPO

The IPO is underwritten Merrill Lynch, SVP Leerink, RBC Capital Markets and Kempen. In February, Hoopika, which is supported by Baker Brothers,...

IPO: Marinomed sets offer price

According to the Austrian formulation specialist, 299,000 new bearer shares were placed with investors consisting of 260,000 shares from the base...

Evotec and Indivumed join forces in CRC

Indivumed will contribute the CRC patient cohort of its standardised multi-omics cancer biobank (IndivuType), which retains unique patterns of...